Hereditary angioedema: Beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture

Allergy, Asthma and Clinical Immunology

Volumn 7, Issue 1, 2011, Pages

  Bowen, Tom ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; ICATIBANT; KALLIKREIN INHIBITOR; RECOMBINANT C1 INHIBITOR; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; CLINICAL EFFECTIVENESS; CONSENSUS DEVELOPMENT; DATA BASE; DRUG INDUSTRY; HEALTH CARE COST; HEMOPHILIA; HUMAN; IMMUNE DEFICIENCY; MEDICAL SOCIETY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE;

EID: 84856446536     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-7-1     Document Type: Review

References (44)

1. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygoeren-Pürsün E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan D, Rowe A, Stark D, Sur S, Tsai E, Warrington R, Waserman S, Ameratunga R, Bernstein J, Björkander J, Brosz K, Brosz J, Bygum A, Caballero T, Frank M, Fust G, Harmat G, Kanani A, Kreuz W, Levi M, Li H, Martinez-Saguer I, Moldovan D, Nagy I, Nielsen EW, Nordenfelt P, Reshef A, Rusicke E, Smith-Foltz S, Späth P, Varga L, Xiang ZY. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010, 6:24. 10.1186/1710-1492-6-24, 2921362, 20667127.
2. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, Craig T, Grant JA, Hurewitz D, Bielory L, Cartwright WE, Koleilat M, Ryan W, Schaefer O, Manning M, Patel P, Bernstein JA, Friedman RA, Wilkinson R, Tanner D, Kohler G, Gunther G, Levy R, McClellan J, Redhead J, Guss D, Heyman E, Blumenstein BA, Kalfus I, Frank MM. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010, 363:513-22. 10.1056/NEJMoa0805538, 20818886.
3. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010, 126:821-827. e14, 10.1016/j.jaci.2010.07.021, 20920772.
4. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010, 363:532-41. Erratum in: N Engl J Med. 2010, 363:1486, 10.1056/NEJMoa0906393, 20818888.
5. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010, 363:523-31. 10.1056/NEJMoa0905079, 20818887.
6. Craig TJ, Wasserman RL, Levy RJ, Bewtra AK, Schneider L, Packer F, Yang WH, Keinecke HO, Kiessling PC. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 2010, 30:823-9. 10.1007/s10875-010-9442-1, 2970824, 20635155.
7. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtułowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Bernstein JA. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009, 124:801-8. 10.1016/j.jaci.2009.07.017, 19767078.
8. Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010, 104:523-9. 10.1016/j.anai.2010.04.012, 20568386.
9. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996, 334:1630-1634. 10.1056/NEJM199606203342503, 8628358.
10. Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, Zerlauth G, Schwarz HP. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998, 38:540-9. 10.1046/j.1537-2995.1998.38698326333.x, 9661687.
11. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972, 286:808-12. 10.1056/NEJM197204132861503, 4551861.
12. Blohme G. Treatment of hereditary angioneurotic oedema with tranexamic acid: A random double-blind cross-over study. Acta Med Scand 1972, 192:293-298. 10.1111/j.0954-6820.1972.tb04818.x, 4562897.
13. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976, 295:1444-8. 10.1056/NEJM197612232952602, 792688.
14. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011, 66(2):192-6. 10.1111/j.1398-9995.2010.02433.x, 21039598.
15. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008, 100:153-61. 10.1016/S1081-1206(10)60424-3, 18320917.
16. Maurer M, Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. J Dtsch Dermatol Ges 2010,
17. Maurer M, Magerl M. Hereditary angioedema: an update on available therapeutic options. J Dtsch Dermatol Ges 2010, 8(9):663-72.
18. Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L, Varga L, Martinez-Saguer I, Aygören-Pürsün E, Binkley K, Zuraw B, Davis A, Hebert J, Ritchie B, Burnham J, Castaldo A, Menendez A, Nagy I, Harmat G, Bucher C, Lacuesta G, Issekutz A, Warrington R, Yang W, Dean J, Kanani A, Stark D, McCusker C, Wagner E, Rivard GE, Leith E, Tsai E, MacSween M, Lyanga J, Serushago B, Leznoff A, Waserman S, de Serres J. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol 2004, 114:629-37. 10.1016/j.jaci.2004.06.043, 15356569.
19. Strawczynski H, Stachewitsch A, Morgenstern G, Shaw ME. Delivery of care to hemophiliac children: home care versus hospitalization. Pediatrics 1973, 51:986-991.
20. Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008, 14(4):743-52. 10.1111/j.1365-2516.2008.01664.x, 18422610.
21. Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, Schellenberg R, Warrington R, Easton D, Anderson D, Hume H. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev 2010, 24(Suppl 1):S28-50. Review, 10.1016/j.tmrv.2009.09.011, 19962579.
22. Simons FE. Epinephrine auto-injectors: first-aid treatment still out of reach for many at risk of anaphylaxis in the community. Ann Allergy Asthma Immunol 2009, 102:403-9. 10.1016/S1081-1206(10)60512-1, 19492662.
23. FitzGerald JM, Sears MR, Boulet LP, Becker AB, McIvor AR, Ernst P, Smiljanic-Georgijev NM, Lee JS, . Canadian Investigators Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 2003, 10:427-34. Canadian Investigators.
24. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010, 104:314-320. 10.1016/j.anai.2010.01.024, 20408341.
25. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004, 114:S51-131. 10.1016/j.jaci.2004.06.047, 15356535.
26. Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, Farkas H, Varga L, Zingale LC, Binkley K, Wagner E, Adomaitis P, Brosz K, Burnham J, Warrington R, Kalicinsky C, Mace S, McCusker C, Schellenberg R, Celeste L, Hebert J, Valentine K, Poon MC, Serushago B, Neurath D, Yang W, Lacuesta G, Issekutz A, Hamed A, Kamra P, Dean J, Kanani A, Stark D, Rivard GE, Leith E, Tsai E, Waserman S, Keith PK, Page D, Marchesin S, Longhurst HJ, Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Harmat G, Füst G, Li H, Bouillet L, Caballero T, Moldovan D, Späth PJ, Smith-Foltz S, Nagy I, Nielsen EW, Bucher C, Nordenfelt P, Xiang ZY. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008, 100(Suppl 2):S30-40. 10.1016/S1081-1206(10)60584-4, 18220150.
27. Hurewitz D, Grant JA, Busse P, Davis-Lorton M, Baker J, Riedl M, Banerji A, Levy R, Craig TJ, Kalfus I, Broom C, Villano S, Uknis M, Tillotson G, . The Cinryze Study Group Open-label Use of Nanofiltered C1 Esterase Inhibitor (human) (nf-C1 INH) for the Prophylaxis of Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects. 2010 WAO International Scientific Conference, Dubai, December 7th, 2010, Paper 2009 The Cinryze Study Group.
28. Zuraw B, Baker J, Hurewitz D, White M, Vegh A, Bielory L, Lumry W, Riedl M, Davis-Lorton M, Levy R, Grant JA, Busse P, Banerji A, Li HH, Kalfus I, Broom C, Villan S, Uknis M, Tillotson G, . The Cinryz Study Group Open-Label Use of Nanofiltered C1 Esterase Inhibitor (Human) for the Prophylaxis of Hereditary Angioedema (HAE) Attacks. 2010 WAO International Scientific Conference, Dubai, December 7th, 2010, Paper 2007 The Cinryz Study Group.
29. Bouillet L. Hereditary angioedema in women. Allergy Asthma Clin Immunol 2010, 6(1):17. 10.1186/1710-1492-6-17, 2918592, 20667120.
30. Czaller I, Visy B, Csuka D, Füst G, Tóth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol 2010, 152:44-9. 10.1016/j.ejogrb.2010.05.008, 20541309.
31. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol 2010, 6(1):18. 10.1186/1710-1492-6-18, 2920237, 20667121.
32. Füst G, Farkas H, Csuka D, Varga L, Bork K. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 2010,
33. Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, Bjorkander J, Bork K, Bouillet L, Boysen H, Bygum A, Caballero T, Cicardi M, Dempster J, Gompels M, Gooi J, Grigoriadou S, Huffer U, Kreuz W, Levi MM, Long J, Martinez-Saguer I, Raguet M, Reshef A, Bowen T, Zuraw B. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010, 6(1):22. 10.1186/1710-1492-6-22, 2922091, 20667125.
34. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009, 19:147-51.
35. Aygoeren-Puersuen E, Martinez-Saguer I, Rusicke E, Kreuz W. On demand treatment and home therapy of hereditary angioedema in Germany -the Frankfurt experience. Allergy Asthma Clin Immunol 2010, 6:21. 10.1186/1710-1492-6-21, 2920239, 20667124.
36. Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, Rusicke E, Heller C, Klingebiel T. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009, 49:1987-95. 10.1111/j.1537-2995.2009.02230.x, 19497056.
37. Keating GM. Human C1-esterase inhibitor concentrae (Berinert®). BioDrugs 2009, 23(6):399-406. 10.2165/11201100-000000000-00000, 19894781.
38. De Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003, 29:247-54. 10.1016/j.transci.2003.08.006, 14572817.
39. Craig T, Riedl M, Dykewicz MS, Gower RG, Baker J, Edelman FJ, Hurewitz D, Jacobs J, Kalfus I. When is prophylaxis for hereditary angioedema necessary?. Ann Allergy Asthma Immunol 2009, 102:366-72. 10.1016/S1081-1206(10)60506-6, 19492656.
40. Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 2011, 154(1):81-8. Epub 2010 Jul 27, 10.1159/000319213, 20664282.
41. Bork K, Fremann S, Kreuz W. Long-term safety of C1 inhibitor concentrate in the treatment of acute hereditary angioedema attacks. EAACI 2010, Abstract.
42. Bork K. Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions. Expert Rev Clin Immunol 2008, 4(1):13-20. 10.1586/1744666X.4.1.13, 20477582.
43. Soucie JM, Symons J, Evatt B, Brettler D, Huszti H, Linden J. Hemophilia Surveillance System Project Investigators. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001, 7:198-206. 10.1046/j.1365-2516.2001.00484.x, 11260280.
44. Chorba TL, Holman RC, Strine TW, Clarke MJ, Evatt BL. Changes in longevity and causes of death among persons with hemophilia A. Am J Hematol 1994, 45:112-21. 10.1002/ajh.2830450204, 8141117.